Telepharmacy and Quality of Medication Use in Rural Areas, 2013–2019

Shweta Pathak, MPH, PhD; Mitchell Haynes, PharmD; Dima M. Qato, PharmD, PhD, MPH; Benjamin Y. Urick, PharmD, PhD

Methods
We obtained dispensing data for the first 18 months of operation from 3 telepharmacies and 3 traditional pharmacies located in the upper Midwest. We evaluated adherence for noninsulin diabetes medications, renin-angiotensin system antagonists, and statins, as well as inappropriate use of high-risk medications in older adults and statin use in persons with diabetes. All metrics were calculated using Medicare Part D specifications. We estimated the differences between telepharmacies serving rural areas and traditional pharmacies using generalized linear regression. We adjusted our models for potential sociodemographic and clinical confounders.

Results
A total of 2,832 patients contributed 4,402 observations to the quality measures. After covariate adjustment, we observed no significant differences between telepharmacies and traditional pharmacies for noninsulin diabetes medications, renin-angiotensin system antagonists, and statins. However, high-risk medications use in persons with diabetes was higher in telepharmacies than traditional pharmacies.

Conclusion
We found that the quality of medication use at telepharmacies that serve rural areas was no worse than at traditional pharmacies. For communities considering the adoption of telepharmacy, results indicate that telepharmacies provide a suitable solution for expanding medication access and that using telepharmacy would not negatively affect the quality of medication use.
medication access that negatively affect medication adherence (5). Decreasing adherence rates lead to greater disease progression and create a substantial financial burden on the health care system (6).

A potential solution for maintaining medication access in rural communities is telepharmacy, which is the provision of patient care by pharmacists through the use of telecommunication or other technologies (7). In the community setting, telepharmacy most often replaces a physical check of patient adherence by a pharmacist with a remote check by a pharmacist. Filling prescriptions by a pharmacy technician also occurs under remote supervision. Additionally, patient counseling services are delivered by telephone or by video connection, as needed (8).

Although regulatory restrictions on telepharmacy have eased in recent years, as of 2016, less than half of all US states had rules or legislation authorizing telepharmacy practice (9). The safety of telepharmacy services has been explored to some extent (10,11), but the effects of telepharmacy on the quality of medication use is largely unknown. Limiting physical access to a pharmacist might negatively influence the quality of medication use, and this uncertainty has created barriers for the implementation of regulations that make telepharmacy licensure possible (12). The primary objective of our study was to evaluate the relationship between telepharmacy services in rural areas and the quality of medication use.

Methods

Our cross-sectional study used retrospective data from the dispensing records of 3 pairs of telepharmacies and the traditional pharmacies that supported them. Telepharmacies were located in smaller rural communities and served a more rural population than the traditional pharmacies. The participating pharmacies are part of a commercial chain located in the upper Midwest region of the United States. Data were obtained from 15 to 18 months for each telepharmacy–traditional pharmacy pair, starting with the opening date of the telepharmacy. An uptake period of 3 months was allowed for the establishment of operations, and the subsequent 12-month observation period was used for quality measurement. Each telepharmacy–traditional pair had different evaluation periods that were based on the opening date of telepharmacy services at each telepharmacy site. The date ranges for telepharmacy–traditional pharmacy pairs were 1) April 1, 2013, to October 31, 2014; 2) May 1, 2015, to November 30, 2016; and 3) October 2, 2017, to January 11, 2019. The University of North Carolina at Chapel Hill’s Institutional Review Board approved the study.

We examined more than 150,000 dispensing records for 10,923 patients, of which, 8,786 patients met our overall population eligibility of adults aged 18 or older. Our primary exposure variable was the use of either telepharmacy or traditional pharmacy for medication management. Patient attribution to telepharmacy or traditional pharmacy was determined separately for each quality measure, according to the site where the patient filled at least 50% of their measure-eligible medications. Outcomes were assessed for 5 quality measures from 2 domains of quality of medication use: medication adherence and inappropriate medication use. Patients were eligible for inclusion in our sample if they met the inclusion criteria for any 1 of the 5 quality measures.

Medication adherence

Medication adherence was evaluated for 3 common classes of medications: 1) noninsulin diabetes medications (NIDMs), 2) renin-angiotensin system antagonists (RASAs), and 3) statins. Each medication class is included in Medicare Part D Star Rating measures and Part D measure specifications (13), developed by the Pharmacy Quality Alliance (14) and endorsed by the National Quality Forum (15). Proportion of days covered (PDC), which is the preferred method to measure adherence (14), was used to assess patient adherence to these drug therapies. The PDC method assesses the percentage of patients covered by prescription claims for the same drug or for another drug in the same therapeutic class within a given period. Measure specifications for NIDM, RASA, and statin adherence require a denominator of patients aged 18 or older with at least 2 fills in the specified medication classes during the measurement year. Patients in the denominator with a PDC at 80% or higher (conventional cut-off) across the classes of medications were considered adherent to a given class of medication. A binary indicator of adherence was created for every patient who met measure specifications in the 12-month post-uptake window of their pharmacy.

Inappropriate medication use

Inappropriate medication use was assessed using measures that are also part of Medicare Star Ratings. These measures were 1) use of high-risk medications (HRM) in the elderly and 2) statin use in persons with diabetes (SUPD). HRM eligibility, by definition, applies only to people aged 65 or older. The HRM measure includes all patients aged 65 or older as eligible for the measure denominator. Eligible patients who received 2 or more prescription fills for the same HRM class during the measurement period were included in the numerator. For the SUPD measure, denominator-eligible patients were aged 40 to 75 years with at least 2 diabetes medication fills during the measurement period. Patients in the denominator who received a statin medication fill during the measurement period were included in the numerator.

Like medication adherence measures, a binary indicator of inappropriate medication use was created for each patient who met the measure specification criteria within the 12-month post-uptake
window of their pharmacy. For the SUPD measure, we found that all denominator-eligible patients in the telepharmacy Pair 1 site met the numerator specifications for this measure, making the lack of variation impossible to accurately assess the differential effect of pharmacy type on the outcome.

Covariates

Covariates of patient age, sex, patient location (rural or urban), payer (Medicaid or other), patient risk indicator (low, moderate and high), and telepharmacy-traditional pair indicators were used to control for variations in observations on the basis of patient demographic and clinical factors. Because dispensing data for the same patient can appear across different points in time for different quality measures, the first fill date for eligible patients within each measure was used to calculate patient age. A Medicaid and non-Medicaid payer indicator was developed as a proxy for patient socioeconomic status. Patients were flagged as Medicaid payers if they had a prescription with Medicaid as the primary or secondary biller. Rural and urban classifications were made by linking county classification of rurality (16) to patient zip codes through a county-zip code crosswalk (17). The original classification scheme by the US Department of Agriculture’s Economic Research Service has 6 rural categories and 3 urban categories (16), which were combined into a binary indicator. Most urban patient zip codes were from counties of a population size of 250,000 or less, although rural patients were from a population size of 2,500 to 19,999. A pharmacy pair indicator was used to absorb any additional geographic or practice-related variation not accounted for by other covariates in the study.

Finally, an indicator of relative patient risk was derived by calculating medication counts for eligible patients within each quality measure. The medication count was determined by the count of distinct therapeutic classes of dispensed medications and was used to categorize prescription burden of patients into relative categories of low, moderate, and high risk based on the tercile of the distribution of the medication counts for each quality measure (18). This risk indicator was a proxy for disease severity in the covariate-adjusted models. A sensitivity analysis, using an alternative risk indicator for prescription burden categories of low polypharmacy (0–4), polypharmacy (5–9), and hyperpolypharmacy (≥9) using conventional polypharmacy cut-offs (19), was also performed.

Statistical analysis

All variables were summarized by using counts and percentages for categorical variables and means, standard deviation, and interquartile ranges for continuous variables. Patient population characteristics were compared within telepharmacies and traditional pharmacies by using χ2 tests of proportions for categorical variables and Student t tests for continuous variables.

The effect of observations clustered within pharmacies on estimates was accounted for by using pharmacy as a repeated measure in generalized estimating equations (GEE), an extension of a generalized linear model. Additionally, binomial distributions with logit links were used to model all outcomes. This approach accounted for within-pharmacy heteroscedasticity to produce population-averaged estimates of binary outcomes. Unadjusted GEE models with only the pharmacy indicator and covariate-adjusted models were assessed for all 5 measures. Beta coefficients derived from unadjusted and adjusted models were converted to odds ratios for ease of interpretation. Additionally, least square-means for adjusted models and 95% confidence intervals for all models were estimated. All analyses were conducted using SAS version 9.4 (SAS Institute Inc).

Results

Our final data set consisted of 2,832 patients who met eligibility criteria for at least 1 of our 5 measures. These patients contributed 4,402 observations to quality measures. Tercile-based risk stratification of patients yielded varied medication count cutoffs for each measure. The cut-off between low and moderate risk was 6 for NIDM, 5 for RASA, 5 for statins, 2 for HRM, and 6 for SUPD. The cut-off between moderate and high risk was 10 for NIDM, 9 for RASA, 9 for statins, 6 for HRM, and 10 for SUPD. More than 20% (661/2832 = 23.3%) of patients in our study received services through telepharmacies. Of 2,832 patients, pharmacy Pair 1 contributed 43.4% (n = 1,230), pharmacy Pair 2 contributed 37.0% (n = 1,049) and pharmacy Pair 3 contributed 19.5% (n = 553). The proportion of patients who used telepharmacies was 5% (148 of 1,230) in pharmacy Pair 1, 30.4% (319 of 1,049) in pharmacy Pair 2, and 35.1% (194 of 553) in pharmacy Pair 3. We observed no significant differences between telepharmacies and traditional pharmacies in population characteristics, such as patient age, sex, or payer (Table 1). Telepharmacies, however, had a significantly higher proportion (χ2 statistic, 352.2; P < .001) of patients from rural residential areas (84.1%; 556 of 661) than traditional pharmacies (27.8%; 603 of 2,171). Conversely, we observed a significantly higher proportion (χ2 statistic, 12.8; P = .002) of patient risk among those using traditional pharmacies (25.6% 555 of 2,171) than telepharmacies (21.5%; 142 of 661).

For the adherence measures and SUPD, we found more male than female patients, and a greater proportion of the population was younger than 65. However, for the HRM measure, we found more...
female than male patients. Similarly, a higher proportion of patients were from urban residential areas in all measures except SUPD, where the proportion of patients from rural residential areas (50.3%) was almost equal to patients from urban residential areas (50.3%). Prevalence of adherence was 73.2% (188 of 257) for NIDMs, 75.6% (731 of 967) for RASAs, and 73.0% (755 of 1034) for statins. The prevalence of HRM use was 8.3% (164 of 1985), and the use of statins among diabetes patients was 66.0% (105 of 159) (Table 2). Covariate adjustment affected all quality measures (Table 3). After covariate adjustment, we observed no significant difference in adherence between telepharmacies and traditional pharmacies for NIDMs, RASAs, statin medications, or HRM. Predicted margins from adjusted models indicate proportions of adherence and inappropriate use for variables in the models (Table 4). Patients with diabetes who used telepharmacies; however, had a significantly higher likelihood of statin use (P < .001) than those using traditional pharmacies. Except for SUPD (83% vs 75%), the differences in the predicted margins for telepharmacies and traditional pharmacies were not significant. Sensitivity analysis using polypharmacy cut-offs did not meaningfully change the results for any of our quality measures.

Discussion

This is the first study to evaluate differences in the quality of medication use between telepharmacies in rural areas and traditional pharmacies by using a broad set of standardized measures. We found that the quality of telepharmacies, as assessed by medication adherence and appropriateness, was no worse than in the traditional pharmacies that supported them. Substantial demographic and clinical differences, however, were observed in the populations served by the 2 pharmacy types. Telepharmacy patients were more likely to reside in rural areas and had a lower medication count. When accounting for these potential confounders, no significant differences were observed between telepharmacy and traditional pharmacies, except for the SUPD measure, on which telepharmacies scored higher. Additional data are needed to confirm that the lack of significance for the HRM measure was not a result of type 2 error.

Our findings on medication adherence support findings from a previous study (20), which found no difference in adherence rates among patients at an urban telepharmacy and those at a retail chain pharmacy. Unlike that study, our study assessed adherence to medications by using standardized measure specifications and examined additional measures of quality, such as inappropriate use. Moreover, our study used data from multiple pairs of telepharmacies in rural areas and traditional pharmacies, increasing our sample size and allowing us to use stronger evaluation methods for assessing our outcomes.

Coupled with safety data from previous studies (10,11), our study can inform boards of pharmacy about the positive relationship between telepharmacy practice and the quality of medication use. Our study might be useful as boards consider this alternative practice model to support their public mission of expanding medication access and improving population health in underserved communities in rural areas. Additionally, for community pharmacy owners and health care institutions considering new telepharmacy operations, our research suggests that new telepharmacies are likely to perform similarly to existing pharmacies that will support them. Establishment of telepharmacies, therefore, might not necessarily place organizations at an additional risk for performance-related penalties, which have become common among third-party payers in the United States (21).

Our study can also inform public health officials, researchers, and policy makers considering telepharmacy as an alternative to increase medication access in communities with poor access to medications. A common term for these communities is pharmacy deserts, and pharmacy deserts are prevalent in both rural and urban areas (22,23). Urban telepharmacies might have similar relative qualities to rural telepharmacies; however, boards of pharmacy, public health leaders, and policy makers should carefully consider regulations that limit the geographic scope of telepharmacies until a better understanding of the implications on medication access and quality of telepharmacies in urban areas is obtained.

Our study had several limitations, primarily as a result of the use of dispensing records for assessment of outcomes and the small number of pharmacies. Dispensing data provide limited information on sociodemographic and clinical factors that can affect the quality of medication use. We addressed this limitation to the extent possible by creating indicators for patient rurality, Medicaid status, and patient risk. Additionally, dispensing data do not capture the complete spectrum of pharmacies visited by patients. It is unlikely, however, that the use of outside pharmacies varied systematically by pharmacy type, and therefore any bias would be balanced across cohorts.

Differences in community pharmacy practice in rural and urban areas (24) might have influenced our findings of telepharmacy and traditional pharmacy outcomes, but we were unable to disentangle those differences in our study. Finally, because telepharmacy practice can differ across states (9), our findings are only generalizable to similar pharmacies serving similar populations. Additional study is needed to evaluate the relative quality of telepharmacies in urban areas and other demographically diverse settings.

Our study indicates that the quality of medication use at telepharmacies serving rural areas is similar to the quality provided through traditional pharmacies. Our findings can be used to in-
form public health policy makers on the suitability of telepharmacy as one solution for improving medication access and facilitating population health in rural pharmacy deserts. Moreover, our results support telepharmacy deregulation and imply that, for institutions participating in alternative payment models, contracting with telepharmacies to dispense medications should not negatively affect patient health or affect quality. Future studies should consider evaluating differences in medication quality for telepharmacies using other outcomes, such as glycosylated hemoglobin, and in other settings, such as urban telepharmacies.

Acknowledgments

This study was supported by funds from Cardinal Health, a global, integrated health company that provides telepharmacy solutions to pharmacies. Cardinal Health was not involved in the collection, analysis, interpretation of data, writing this report, or the decision to submit this report for publication. All authors of this article declare that there are no financial conflicts of interest to disclose. No borrowed materials, copyrighted surveys, instruments, or tools were used for this report. The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Author Information

Corresponding Author: Shweta Pathak, MPH, PhD, UNC Eshelman School of Pharmacy, Center for Medication Optimization, 2400 Kerr Hall, 301 Pharmacy Lane, Chapel Hill, NC 27599. Email: shpathak@email.unc.edu.

Author Affiliations: 1 University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina. 2 University of Illinois College of Pharmacy, Chicago, Illinois.

References

1. Skoufalos A, Clarke JL, Ellis DR, Shepard VL, Rula EY. Rural aging in America: proceedings of the 2017 Connectivity Summit. Popul Health Manag 2017;20(S2):S1–10.
2. Todd K, Westfall K, Doucette B, Ullrich F, Mueller K, Rural Health Research & Policy Centers, et al. Causes and consequences of rural pharmacy closures: a multi-case study. Rural Policy Brief 2013;(2013 11):1–4.
3. Salako A, Ullrich F, Mueller KJ. Update: independently owned pharmacy closures in rural America, 2003–2018. Rural Policy Brief 2018;2018(2):1–6.
4. The IQVIA Institute. Medicine use and spending in the US. 2019. https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023. Accessed December 17, 2019.
5. Qato DM, Alexander GC, Chakraborty A, Guadamuz JS, Jackson JW. Association between pharmacy closures and adherence to cardiovascular medications among older US adults. JAMA Netw Open 2019;2(4):e192606.
6. Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open 2018;8(1):e016982.
7. National Association of Boards of Pharmacy. Model state pharmacy act and model rules of the national association of boards of pharmacy 2018. https://nabp.pharmacy/publications-reports/resource-documents/model-pharmacy-act-rules. Accessed November 28, 2018.
8. Sherman J. Telepharmacy? A promising alternative for rural communities. Pharmacy Times 2007. https://www.pharmacytimes.com/publications/issue/2007-02/2007-02-6296. Accessed Dec 17, 2019.
9. Tzanetakos G, Ullrich F, Mueller K. Telepharmacy rules and statutes: a 50-state survey. Am J Med Res 2017;(2017):1–4.
10. Scott DM, Friessner DL, Rathke AM, Peterson CD, Anderson HC. Differences in medication errors between central and remote site telepharmacies. J Am Pharm Assoc 2012;52(5):e97–e104.
11. Friessner DL, Scott DM, Rathke AM, Peterson CD, Anderson HC. Do remote community telepharmacies have higher medication error rates than traditional community pharmacies? Evidence from the North Dakota Telepharmacy Project. J Am Pharm Assoc (2003) 2011;51(5):580–90.
12. Steckler T. Telepharmacy: controversy and promise. J Pharm Technol 2016;32(6):227–9.
13. Centers for Medicare & Medicaid Services. Medicare 2018 part C and D star ratings technical notes 2017. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCoverGenIn/Downloads/2018-Star-Ratings-Technical-Notes-2017_09_06.pdf. Accessed May 15, 2020.
14. Nau DP. Proportion of days covered (PDC) as a preferred method of measuring medication adherence. http://ep.yimg.com/ty/cdn/epill/pdcmpr.pdf. Accessed February 16, 2019.
15. McGinley P. National Quality Forum endorses measures to improve medication safety and quality. Healthcare Finance News 2009. https://www.healthcarefinancenews.com/press-release/national-quality-forum-endorse-mesures-improve-medication-safety-and-quality. Accessed April 14, 2020.
16. United States Department of Agriculture. USDA Economic Research Service rural-urban continuum codes. https://www.ers.usda.gov/data-products/rural-urban-continuum-codes.aspx. Accessed April 9, 2019.

17. US Department of Housing and Urban Development. HUD USPS ZIP code crosswalk files. https://www.huduser.gov/portal/datasets/usps_crosswalk.html. Accessed April 9 2016.

18. Schmittidiel JA, Raebel MA, Dyer W, Xu S, Goodrich GK, Schroeder EB, et al. Prescription medication burden in patients with newly diagnosed diabetes: a SUrveillance, PREvention, and ManagEmnt of Diabetes Mellitus (SUPREME-DM) study. J Am Pharm Assoc (2003) 2014;54(4):374–82.

19. Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: evaluating risks and deprescribing. Am Fam Physician 2019;100(1):32–8.

20. Hudd TR, Tataronis GR. The impact of an urban telepharmacy on patient medication adherence in a federally qualified health center. J Pharm Technol 2011;27(3):117–22.

21. Health Care Payment Learning & Action Network. Measuring progress: adoption of alternative payment models in commercial, Medicaid, Medicare advantage, and Medicare fee-for-service programs, 2018. https://hcp-lan.org/2018-apm-measurement/. Accessed Dec 9, 2019.

22. Pednekar P, Peterson A. Mapping pharmacy deserts and determining accessibility to community pharmacy services for elderly enrolled in a State Pharmaceutical Assistance Program. PLoS One 2018;13(6):e0198173.

23. Qato DM, Daviglus ML, Wilder J, Lee T, Qato D, Lambert B. ‘Pharmacy deserts’ are prevalent in Chicago’s predominantly minority communities, raising medication access concerns. Health Aff (Millwood) 2014;33(11):1958–65.

24. Howarth HD, Peterson GM, Jackson SL. Does rural and urban community pharmacy practice differ? A narrative systematic review. Int J Pharm Pract 2020;28(1):3–12.
Table 1. Comparison of Overall Patient Characteristics by Pharmacy type to Evaluate Quality of Medication Use, 2013–2019

| Characteristics       | Traditional, No. (%)\(a\) (n = 2,171) | Telepharmacy, No. (%)\(a\) (n = 661) | P Value |
|-----------------------|----------------------------------------|-------------------------------------|---------|
| **Patient sex**       |                                        |                                     |         |
| Female                | 1,100 (50.7)                           | 336 (50.8)                          | .94\(b\) |
| Male                  | 1,071 (49.3)                           | 325 (49.2)                          |         |
| **Age group, y**      |                                        |                                     |         |
| 18–49                 | 182 (8.4)                              | 57 (8.6)                            | .10\(b\) |
| 50–64                 | 509 (23.4)                             | 134 (20.3)                          |         |
| 65–74                 | 750 (34.5)                             | 261 (39.5)                          |         |
| >74                   | 730 (33.6)                             | 209 (31.6)                          |         |
| **Patient location**  |                                        |                                     |         |
| Urban                 | 1,568 (72.2)                           | 105 (15.9)                          | <.001\(b\) |
| Rural                 | 603 (27.8)                             | 556 (84.1)                          |         |
| **Patient risk\(d\)**|                                        |                                     |         |
| High                  | 555 (25.6)                             | 142 (21.5)                          | .002\(b\) |
| Moderate              | 816 (37.6)                             | 225 (34.0)                          |         |
| Low                   | 800 (36.8)                             | 294 (44.5)                          |         |
| **Payer**             |                                        |                                     |         |
| Medicaid              | 66 (3.0)                               | 28 (4.2)                            | .13\(b) |
| Other                 | 2,105 (97.0)                           | 633 (95.8)                          |         |
| **Patient age, mean (SD), y** | 68.5 (13.1) | 68.2 (12.9) | .63\(c\) |
| **No. of medications, mean (SD)\(e\)** | 6.3 (4.5) | 5.5 (4.2) | <.001\(c\) |

\(a\) Percentages may not add to 100 because of rounding.

\(b\) Derived from \(\chi^2\) test.

\(c\) Derived from Student t test.

\(d\) Tercile-based stratification of the medication counts for measure-eligible patients; varies for each quality measure.

\(e\) Number of medications calculated as the count of distinct classes of dispensed medications.
Table 2. Description of Patient (N = 2,832) Characteristics by Outcomes for Medication Adherence and Inappropriate Use, 2013–2019

| Characteristics | Adherence to Noninsulin Diabetes Medications (n = 257) | Adherence to Renin-Angiotensin System Antagonist (n = 967) | Adherence to Statins (n = 1,034) | Use of High-Risk Medications (n = 1,985) | Statin Use in Persons With Diabetes (n = 159) |
|----------------|------------------------------------------------------|-----------------------------------------------------------|----------------------------------|------------------------------------------|---------------------------------------------|
| **Patient sex** |                                                      |                                                           |                                  |                                          |                                             |
| Female         | 125 (48.6)                                           | 436 (45.1)                                                | 482 (46.6)                       | 1,104 (55.6)                             | 73 (45.9)                                   |
| Male           | 132 (51.4)                                           | 531 (54.9)                                                | 552 (53.4)                       | 881 (44.4)                               | 86 (54.1)                                   |
| **Age, y**     |                                                      |                                                           |                                  |                                          |                                             |
| 18-49          | 38 (14.8)                                            | 151 (15.6)                                                | 108 (10.4)                       | —                                        | 22 (13.8)                                   |
| 50-64          | 116 (45.1)                                           | 365 (37.7)                                                | 432 (41.8)                       | —                                        | 73 (45.9)                                   |
| 65-74          | 50 (19.5)                                            | 239 (24.7)                                                | 255 (24.7)                       | 1,046 (52.7)                             | 59 (37.1)                                   |
| >74            | 53 (20.6)                                            | 212 (21.9)                                                | 239 (23.1)                       | 939 (47.3)                               | 5 (3.1)                                     |
| **Patient location** |                                             |                                                           |                                  |                                          |                                             |
| Urban          | 168 (65.4)                                           | 603 (62.4)                                                | 698 (67.5)                       | 1,127 (56.8)                             | 79 (49.7)                                   |
| Rural          | 89 (34.6)                                            | 364 (37.6)                                                | 336 (32.5)                       | 858 (43.2)                               | 80 (50.3)                                   |
| **Patient risk** |                                             |                                                           |                                  |                                          |                                             |
| Low            | 73 (28.4)                                            | 298 (30.8)                                                | 305 (29.5)                       | 574 (28.9)                               | 48 (30.2)                                   |
| Moderate       | 93 (36.2)                                            | 341 (35.3)                                                | 378 (36.6)                       | 711 (35.8)                               | 54 (34.0)                                   |
| High           | 91 (35.4)                                            | 328 (33.9)                                                | 351 (33.9)                       | 700 (35.3)                               | 57 (35.8)                                   |
| **Payer**      |                                                      |                                                           |                                  |                                          |                                             |
| Other          | 234 (91.1)                                           | 916 (94.7)                                                | 977 (94.5)                       | 1,970 (99.2)                             | 144 (90.6)                                  |
| Medicaid       | 23 (8.9)                                             | 51 (5.3)                                                  | 57 (5.5)                         | 15 (0.8)                                 | 15 (9.4)                                    |
| **Pharmacy type** |                                             |                                                           |                                  |                                          |                                             |
| Traditional    | 202 (78.6)                                           | 753 (77.9)                                                | 852 (82.4)                       | 1,510 (76.1)                             | 114 (71.7)                                  |
| Telepharmacy   | 55 (21.4)                                            | 214 (22.1)                                                | 182 (17.6)                       | 475 (23.9)                               | 45 (28.3)                                   |
| **Pharmacy pairs** |                                             |                                                           |                                  |                                          |                                             |
| Pair 3         | 35 (13.6)                                            | 169 (17.5)                                                | 169 (16.3)                       | 412 (20.8)                               | 38 (23.9)                                   |
| Pair 2         | 90 (35.0)                                            | 335 (34.6)                                                | 307 (29.7)                       | 804 (40.5)                               | 121 (76.1)                                  |
| Pair 1         | 132 (51.4)                                           | 463 (47.9)                                                | 558 (54.0)                       | 769 (38.7)                               | —                                           |
| **Prevalence of Adherence or Inappropriate Use** |                                             |                                                           |                                  |                                          |                                             |
| All values are number (percentage) unless otherwise indicated. |                                             |                                                           |                                  |                                          |                                             |
| **Use of high-risk medications applies only to patients aged 65 or older, as per measure specifications.** |                                             |                                                           |                                  |                                          |                                             |
| **Tercile-based stratification of the medication count for measure-eligible patients; varies for each quality measure.** |                                             |                                                           |                                  |                                          |                                             |
| **Prevalence defined as all observations that met numerator specifications for each quality measure.** |                                             |                                                           |                                  |                                          |                                             |
| **Number of medications calculated as the count of distinct therapeutic classes of dispensed medications.** |                                             |                                                           |                                  |                                          |                                             |

Abbreviations: —, not applicable; IQR, interquartile range.

Preventing Chronic Disease, Volume 17, E101
Public Health Research, Practice, and Policy
September 2020

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.

8 Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2020/20_0012.htm
Table 3. Unadjusted and Covariate-Adjusted Estimates of the Effect of Pharmacy type on Quality of Medication Use

| Variables                       | Adherence to Noninsulin Diabetes Medications | Adherence to Renin-Angiotensin System Antagonist Medications | Adherence to Statins | Use of High-Risk Medications (≥65 y) | Statin Use in Persons with Diabetes |
|---------------------------------|---------------------------------------------|-------------------------------------------------------------|----------------------|--------------------------------------|-------------------------------------|
|                                 | Quality Measures                             |                                                             | Quality Measures     | Quality Measures                     | Quality Measures                    |
|                                 | Adherence to Noninsulin Diabetes Medications | Adherence to Renin-Angiotensin System Antagonist Medications | Adherence to Statins | Use of High-Risk Medications (≥65 y) | Statin Use in Persons with Diabetes |
| Unadjusted model pharmacy type<sup>a</sup> |                                |                                                             | Quality Measures     | Quality Measures                     | Quality Measures                    |
| Traditional                     | 1 [Reference]                               | 1 [Reference]                                              | 1 [Reference]        | 1 [Reference]                        | 1 [Reference]                       |
| Telepharmacy                    | 0.6 (0.4–0.8) [.001]                        | 1.1 (0.8–1.4) [.60]                                       | 1.0 (0.7–1.7) [.84]  | 0.9 (0.8–1.1) [.20]                  | 0.9 (0.7–1.3) [.80]                  |
| Covariate adjusted model pharmacy type<sup>a</sup> |                                |                                                             | Quality Measures     | Quality Measures                     | Quality Measures                    |
| Traditional                     | 1 [Reference]                               | 1 [Reference]                                              | 1 [Reference]        | 1 [Reference]                        | 1 [Reference]                       |
| Telepharmacy                    | 0.8 (0.5–1.3) [.42]                         | 1.0 (0.9–1.2) [.70]                                       | 1.3 (0.8–2.1) [.30]  | 1.3 (1.0–1.8) [.06]                  | 1.7 (1.3–2.0) [.<.001]               |
| Patient sex                     |                                             |                                                             | Quality Measures     | Quality Measures                     | Quality Measures                    |
| Male                            | 1 [Reference]                               | 1 [Reference]                                              | 1 [Reference]        | 1 [Reference]                        | 1 [Reference]                       |
| Female                          | 1.4 (0.9–2.1) [.15]                         | 0.7 (0.6–1.0) [.02]                                       | 0.9 (0.8–1.1) [.02]  | 1.1 (0.8–1.5) [.71]                  | 0.3 (0.2–0.5) [.<.001]               |
| Age group                       |                                             |                                                             | Quality Measures     | Quality Measures                     | Quality Measures                    |
| 18–49                           | 1 [Reference]                               | 1 [Reference]                                              | 1 [Reference]        | 1 [Reference]                        | 1 [Reference]                       |
| 50–64                           | 3.2 (1.5–7.2) [.004]                        | 1.8 (1.3–2.5) [.001]                                       | 2.1 (1.7–2.4) [.<.001] |                                      |                                     |
| 65–74                           | 6.9 (2.5–16.5) [<.001]                      | 2.5 (1.8–3.3) [.<.001]                                     | 2.6 (2.2–3.2) [.<.001] | 1 [Reference]                        |                                     |
| ≥65                             | –                                           | –                                                           | –                    | 3.9 (2.2–7.2) [.<.001]               |                                     |
| <65                             | –                                           | –                                                           | –                    | 1 [Reference]                        |                                     |
| >74                             | 2.3 (1.4–3.7) [<.001]                       | 2.2 (1.6–3.2) [.001]                                       | 2.2 (1.6–2.9) [<.001] | 0.8 (0.6–1.0) [.03]                  |                                     |
| Patient location                |                                             |                                                             | Quality Measures     | Quality Measures                     | Quality Measures                    |
| Urban                           | 1 [Reference]                               | 1 [Reference]                                              | 1 [Reference]        | 1 [Reference]                        | 1 [Reference]                       |
| Rural                           | 0.4 (0.3–0.6) [<.001]                       | 1.3 (1.1–1.6) [.005]                                       | 0.7 (0.5–0.9) [<.003] | 0.9 (0.6–1.2) [.40]                  | 0.7 (0.5–1.1) [.11]                 |
| Patient risk<sup>d</sup>        |                                             |                                                             | Quality Measures     | Quality Measures                     | Quality Measures                    |
| Low                             | 1 [Reference]                               | 1 [Reference]                                              | 1 [Reference]        | 1 [Reference]                        | 1 [Reference]                       |
| Moderate                        | 0.8 (0.4–1.9) [.69]                         | 1.1 (0.7–1.5) [80]                                        | 0.9 (0.6–1.3) [.50]  | 5.5 (2.9–10.4) [.<.001]              | 1.2 (0.7–2.1) [.49]                 |
| High                            | 1.3 (0.5–3.3) [.52]                         | 0.9 (0.7–1.1) [.40]                                       | 1.3 (1.0–1.5) [.02]  | 19.7 (10.6–36.3) [.<.001]            | 2.1 (1.6–2.8) [.<.001]              |
| Payer                           |                                             |                                                             | Quality Measures     | Quality Measures                     | Quality Measures                    |
| Medicaid                        | 1 [Reference]                               | 1 [Reference]                                              | 1 [Reference]        | 1 [Reference]                        | 1 [Reference]                       |
| Other                           | 3.9 (2.1–6.9) [<.001]                       | 1.9 (1.1–3.1) [<.02]                                       | 2.1 (1.2–3.8) [.01]  | 1.0 (0.4–2.2) [.94]                  | 0.4 (0.3–0.6) [<.001]               |
| Pharmacy pair                   |                                             |                                                             | Quality Measures     | Quality Measures                     | Quality Measures                    |
| Pair 3                          | 1 [Reference]                               | 1 [Reference]                                              | 1 [Reference]        | 1 [Reference]                        | 1 [Reference]                       |
| Pair 2                          | 3.1 (1.7–5.6) [.001]                        | 1.7 (1.5–1.9) [<.001]                                      | 1.3 (1.0–1.7) [.08]  | 1.1 (1.0–1.3) [.13]                  | 0.8 (0.7–1.0) [.01]                 |
| Pair 1                          | 1.6 (0.9–2.9) [.14]                         | 1.3 (1.1–1.4) [<.001]                                      | 0.6 (0.5–0.7) [<.001] | 1.3 (1.1–1.5) [.01]                  | –                                   |

Abbreviation: –, not applicable.
<sup>a</sup> All values are odds ratio (95% CI) and [P value].
<sup>b</sup> Use of high-risk medications applies only to patients aged 65 or older, as per measure specifications.
<sup>c</sup> Age groups combined for model development; no assessment for pharmacy Pair 1.
<sup>d</sup> Tercile-based stratification of the medication count for measure-eligible patients; varies for each quality measure.
Table 4. Predicted Margins From Adjusted Models of Medication Adherence and Inappropriate Use Using Least Square Means

| Characteristics          | Noninsulin Diabetes Medications Adherence | Renin-Angiotensin System Antagonist Adherence | Statin Adherence | Use of High-Risk Medications\(^b\) | Statin Use in Persons with Diabetes\(^c\) |
|--------------------------|-------------------------------------------|---------------------------------------------|------------------|-----------------------------------|----------------------------------------|
| **Patient sex**          |                                           |                                             |                  |                                   |                                        |
| Male                     | 0.54 (0.46–0.61)                          | 0.73 (0.65–0.79)                            | 0.68 (0.60–0.75) | 0.05 (0.03–0.08)                  | 0.69 (0.65–0.74)                        |
| Female                   | 0.61 (0.54–0.86)                          | 0.67 (0.61–0.72)                            | 0.67 (0.58–0.74) | 0.05 (0.03–0.08)                  | 0.87 (0.81–0.91)                        |
| **Age group**            |                                           |                                             |                  |                                   |                                        |
| 18–49                    | 0.33 (0.21–0.49)                          | 0.57 (0.50–0.63)                            | 0.53 (0.43–0.62) | –                                 | –                                      |
| 50–64                    | 0.62 (0.56–0.68)                          | 0.70 (0.63–0.77)                            | 0.70 (0.61–0.77) | –                                 | –                                      |
| <65                      | –                                         | –                                           | –                 | –                                 | 0.66 (0.63–0.69)                        |
| 65–74                    | 0.78 (0.68–0.85)                          | 0.76 (0.71–0.81)                            | 0.75 (0.67–0.81) | 0.05 (0.03–0.09)                  | –                                      |
| ≥65                      | –                                         | –                                           | –                 | –                                 | 0.88 (0.82–0.93)                        |
| >74                      | 0.54 (0.49–0.58)                          | 0.74 (0.67–0.80)                            | 0.71 (0.63–0.78) | 0.04 (0.03–0.07)                  | –                                      |
| **Patient location**     |                                           |                                             |                  |                                   |                                        |
| Urban                    | 0.67 (0.60–0.73)                          | 0.67 (0.58–0.74)                            | 0.72 (0.63–0.79) | 0.05 (0.03–0.09)                  | 0.82 (0.78–0.85)                        |
| Rural                    | 0.47 (0.42–0.52)                          | 0.73 (0.68–0.77)                            | 0.63 (0.54–0.71) | 0.04 (0.03–0.08)                  | 0.77 (0.69–0.83)                        |
| **Patient risk\(^d\)**  |                                           |                                             |                  |                                   |                                        |
| Low                      | 0.56 (0.41–0.71)                          | 0.70 (0.65–0.75)                            | 0.67 (0.56–0.76) | 0.01 (0.00–0.02)                  | 0.74 (0.67–0.80)                        |
| Moderate                 | 0.52 (0.42–0.62)                          | 0.71 (0.62–0.79)                            | 0.64 (0.56–0.72) | 0.06 (0.04–0.08)                  | 0.77 (0.72–0.82)                        |
| High                     | 0.63 (0.50–0.75)                          | 0.68 (0.61–0.74)                            | 0.72 (0.64–0.78) | 0.17 (0.12–0.25)                  | 0.85 (0.78–0.91)                        |
| **Payer**                |                                           |                                             |                  |                                   |                                        |
| Non-Medicaid             | 0.73 (0.68–0.77)                          | 0.76 (0.75–0.77)                            | 0.75 (0.72–0.78) | 0.05 (0.04–0.06)                  | 0.72 (0.70–0.74)                        |
| Medicaid                 | 0.41 (0.30–0.52)                          | 0.63 (0.50–0.74)                            | 0.59 (0.43–0.73) | 0.05 (0.02–0.12)                  | 0.85 (0.79–0.90)                        |
| **Pharmacy pair**        |                                           |                                             |                  |                                   |                                        |
| Pair 3                   | 0.44 (0.34–0.55)                          | 0.64 (0.58–0.70)                            | 0.70 (0.64–0.75) | 0.04 (0.03–0.07)                  | 0.81 (0.75–0.85)                        |
| Pair 2                   | 0.71 (0.65–0.76)                          | 0.75 (0.69–0.80)                            | 0.75 (0.65–0.82) | 0.05 (0.03–0.08)                  | 0.78 (0.74–0.81)                        |
| Pair 1                   | 0.56 (0.48–0.63)                          | 0.69 (0.64–0.74)                            | 0.57 (0.47–0.66) | 0.05 (0.03–0.09)                  | –                                      |
| **Pharmacy type**        |                                           |                                             |                  |                                   |                                        |
| Traditional              | 0.60 (0.52–0.67)                          | 0.69 (0.65–0.73)                            | 0.65 (0.59–0.70) | 0.04 (0.03–0.07)                  | 0.75 (0.69–0.80)                        |
| Telepharmacy             | 0.55 (0.47–0.63)                          | 0.70 (0.63–0.77)                            | 0.70 (0.58–0.80) | 0.06 (0.03–0.10)                  | 0.83 (0.79–0.87)                        |

Abbreviations: —, not applicable.

a All values are predicted margin (95% CI).

b Use of high-risk medications applies only to patients aged 65 or older, as per measure specifications.

c Age groups combined for model development; no assessment for Pharmacy Pair 1.

d Tercile-based stratification of the medication count for measure-eligible patients; varies for each quality measure.